Biogen (FRA:IDP) Beginning Cash Position : €966 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Biogen Beginning Cash Position?

Biogen's Beginning Cash Position for the quarter that ended in Mar. 2024 was €966 Mil.

Biogen's quarterly Beginning Cash Position declined from Sep. 2023 (€2,453 Mil) to Dec. 2023 (€2,098 Mil) and declined from Dec. 2023 (€2,098 Mil) to Mar. 2024 (€966 Mil).

Biogen's annual Beginning Cash Position increased from Dec. 2021 (€1,178 Mil) to Dec. 2022 (€2,135 Mil) and increased from Dec. 2022 (€2,135 Mil) to Dec. 2023 (€3,135 Mil).

Biogen Beginning Cash Position Historical Data

The historical data trend for Biogen's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Beginning Cash Position Chart

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

1,102.14

2,395.06

1,178.11

2,134.76

3,135.50

Biogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															3,193.63	2,675.04	2,452.88	2,098.01	965.91

Biogen Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Biogen Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Biogen's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (FRA:IDP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (FRA:IDP) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (FRA:IDP) Headlines

No Headlines